#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0183] One group of fluorescent dyes suitable for this method of sequencing is fluorescence resonance energy transfer (FRET) dyes, including donor and acceptor energy fluorescent dyes and linkers such as, for example, Cy3 and Cy5.
1-1	0-1	[	_	_	
1-2	1-5	0183	_	_	
1-3	5-6	]	_	_	
1-4	7-10	One	_	_	
1-5	11-16	group	_	_	
1-6	17-19	of	_	_	
1-7	20-31	fluorescent	_	_	
1-8	32-36	dyes	_	_	
1-9	37-45	suitable	_	_	
1-10	46-49	for	_	_	
1-11	50-54	this	_	_	
1-12	55-61	method	_	_	
1-13	62-64	of	_	_	
1-14	65-75	sequencing	_	_	
1-15	76-78	is	_	_	
1-16	79-91	fluorescence	_	_	
1-17	92-101	resonance	_	_	
1-18	102-108	energy	_	_	
1-19	109-117	transfer	_	_	
1-20	118-119	(	_	_	
1-21	119-123	FRET	_	_	
1-22	123-124	)	_	_	
1-23	125-129	dyes	_	_	
1-24	129-130	,	_	_	
1-25	131-140	including	_	_	
1-26	141-146	donor	_	_	
1-27	147-150	and	_	_	
1-28	151-159	acceptor	_	_	
1-29	160-166	energy	_	_	
1-30	167-178	fluorescent	_	_	
1-31	179-183	dyes	_	_	
1-32	184-187	and	_	_	
1-33	188-195	linkers	_	_	
1-34	196-200	such	_	_	
1-35	201-203	as	_	_	
1-36	203-204	,	_	_	
1-37	205-208	for	_	_	
1-38	209-216	example	_	_	
1-39	216-217	,	_	_	
1-40	218-221	Cy3	_	_	
1-41	222-225	and	_	_	
1-42	226-229	Cy5	_	_	
1-43	229-230	.	_	_	

#Text=FRET is a phenomenon described in, for example, Selvin (1995) Methods in Enzym. 246:300.
2-1	231-235	FRET	_	_	
2-2	236-238	is	_	_	
2-3	239-240	a	_	_	
2-4	241-251	phenomenon	_	_	
2-5	252-261	described	_	_	
2-6	262-264	in	_	_	
2-7	264-265	,	_	_	
2-8	266-269	for	_	_	
2-9	270-277	example	_	_	
2-10	277-278	,	_	_	
2-11	279-285	Selvin	_	_	
2-12	286-287	(	_	_	
2-13	287-291	1995	_	_	
2-14	291-292	)	_	_	
2-15	293-300	Methods	_	_	
2-16	301-303	in	_	_	
2-17	304-309	Enzym	_	_	
2-18	309-310	.	_	_	
2-19	311-314	246	_	_	
2-20	314-315	:	_	_	
2-21	315-318	300	_	_	
2-22	318-319	.	_	_	

#Text=FRET can detect the incorporation of multiple nucleotides into a single oligonucleotide molecule and is, thus, useful for sequencing the encoding oligonucleotides of the invention.
3-1	320-324	FRET	_	_	
3-2	325-328	can	_	_	
3-3	329-335	detect	_	_	
3-4	336-339	the	_	_	
3-5	340-353	incorporation	_	_	
3-6	354-356	of	_	_	
3-7	357-365	multiple	_	_	
3-8	366-377	nucleotides	_	_	
3-9	378-382	into	_	_	
3-10	383-384	a	_	_	
3-11	385-391	single	_	_	
3-12	392-407	oligonucleotide	_	_	
3-13	408-416	molecule	_	_	
3-14	417-420	and	_	_	
3-15	421-423	is	_	_	
3-16	423-424	,	_	_	
3-17	425-429	thus	_	_	
3-18	429-430	,	_	_	
3-19	431-437	useful	_	_	
3-20	438-441	for	_	_	
3-21	442-452	sequencing	_	_	
3-22	453-456	the	_	_	
3-23	457-465	encoding	_	_	
3-24	466-482	oligonucleotides	_	_	
3-25	483-485	of	_	_	
3-26	486-489	the	_	_	
3-27	490-499	invention	_	_	
3-28	499-500	.	_	_	

#Text=Sequencing methods using FRET are described in, for example, PCT Publication No.
4-1	501-511	Sequencing	_	_	
4-2	512-519	methods	_	_	
4-3	520-525	using	_	_	
4-4	526-530	FRET	_	_	
4-5	531-534	are	_	_	
4-6	535-544	described	_	_	
4-7	545-547	in	_	_	
4-8	547-548	,	_	_	
4-9	549-552	for	_	_	
4-10	553-560	example	_	_	
4-11	560-561	,	_	_	
4-12	562-565	PCT	_	_	
4-13	566-577	Publication	_	_	
4-14	578-580	No	_	_	
4-15	580-581	.	_	_	

#Text=WO 2005/080605, the entire contents of which are expressly incorporated by reference.
5-1	582-584	WO	_	_	
5-2	585-589	2005	_	_	
5-3	589-590	/	_	_	
5-4	590-596	080605	_	_	
5-5	596-597	,	_	_	
5-6	598-601	the	_	_	
5-7	602-608	entire	_	_	
5-8	609-617	contents	_	_	
5-9	618-620	of	_	_	
5-10	621-626	which	_	_	
5-11	627-630	are	_	_	
5-12	631-640	expressly	_	_	
5-13	641-653	incorporated	_	_	
5-14	654-656	by	_	_	
5-15	657-666	reference	_	_	
5-16	666-667	.	_	_	

#Text=Alternatively, quantum dots can be used as a labeling moiety on the different types of nucleotides for use in sequencing reactions.
#Text=[0184] Once single ligands are identified by the above-described process, various levels of analysis can be applied to yield structure-activity relationship information and to guide further optimization of the affinity, specificity and bioactivity of the ligand.
6-1	668-681	Alternatively	_	_	
6-2	681-682	,	_	_	
6-3	683-690	quantum	_	_	
6-4	691-695	dots	_	_	
6-5	696-699	can	_	_	
6-6	700-702	be	_	_	
6-7	703-707	used	_	_	
6-8	708-710	as	_	_	
6-9	711-712	a	_	_	
6-10	713-721	labeling	_	_	
6-11	722-728	moiety	_	_	
6-12	729-731	on	_	_	
6-13	732-735	the	_	_	
6-14	736-745	different	_	_	
6-15	746-751	types	_	_	
6-16	752-754	of	_	_	
6-17	755-766	nucleotides	_	_	
6-18	767-770	for	_	_	
6-19	771-774	use	_	_	
6-20	775-777	in	_	_	
6-21	778-788	sequencing	_	_	
6-22	789-798	reactions	_	_	
6-23	798-799	.	_	_	
6-24	800-801	[	_	_	
6-25	801-805	0184	_	_	
6-26	805-806	]	_	_	
6-27	807-811	Once	_	_	
6-28	812-818	single	_	_	
6-29	819-826	ligands	_	_	
6-30	827-830	are	_	_	
6-31	831-841	identified	_	_	
6-32	842-844	by	_	_	
6-33	845-848	the	_	_	
6-34	849-864	above-described	_	_	
6-35	865-872	process	_	_	
6-36	872-873	,	_	_	
6-37	874-881	various	_	_	
6-38	882-888	levels	_	_	
6-39	889-891	of	_	_	
6-40	892-900	analysis	_	_	
6-41	901-904	can	_	_	
6-42	905-907	be	_	_	
6-43	908-915	applied	_	_	
6-44	916-918	to	_	_	
6-45	919-924	yield	_	_	
6-46	925-943	structure-activity	_	_	
6-47	944-956	relationship	_	_	
6-48	957-968	information	_	_	
6-49	969-972	and	_	_	
6-50	973-975	to	_	_	
6-51	976-981	guide	_	_	
6-52	982-989	further	_	_	
6-53	990-1002	optimization	_	_	
6-54	1003-1005	of	_	_	
6-55	1006-1009	the	_	_	
6-56	1010-1018	affinity	_	_	
6-57	1018-1019	,	_	_	
6-58	1020-1031	specificity	_	_	
6-59	1032-1035	and	_	_	
6-60	1036-1047	bioactivity	_	_	
6-61	1048-1050	of	_	_	
6-62	1051-1054	the	_	_	
6-63	1055-1061	ligand	_	_	
6-64	1061-1062	.	_	_	

#Text=For ligands derived from the same scaffold, three-dimensional molecular modeling can be employed to identify significant structural features common to the ligands, thereby generating families of small-molecule ligands that presumably bind at a common site on the target biomolecule.
#Text=[0185] A variety of screening approaches can be used to obtain ligands that possess high affinity for one target but significantly weaker affinity for another closely related target.
7-1	1063-1066	For	_	_	
7-2	1067-1074	ligands	_	_	
7-3	1075-1082	derived	_	_	
7-4	1083-1087	from	_	_	
7-5	1088-1091	the	_	_	
7-6	1092-1096	same	_	_	
7-7	1097-1105	scaffold	_	_	
7-8	1105-1106	,	_	_	
7-9	1107-1124	three-dimensional	_	_	
7-10	1125-1134	molecular	_	_	
7-11	1135-1143	modeling	_	_	
7-12	1144-1147	can	_	_	
7-13	1148-1150	be	_	_	
7-14	1151-1159	employed	_	_	
7-15	1160-1162	to	_	_	
7-16	1163-1171	identify	_	_	
7-17	1172-1183	significant	_	_	
7-18	1184-1194	structural	_	_	
7-19	1195-1203	features	_	_	
7-20	1204-1210	common	_	_	
7-21	1211-1213	to	_	_	
7-22	1214-1217	the	_	_	
7-23	1218-1225	ligands	_	_	
7-24	1225-1226	,	_	_	
7-25	1227-1234	thereby	_	_	
7-26	1235-1245	generating	_	_	
7-27	1246-1254	families	_	_	
7-28	1255-1257	of	_	_	
7-29	1258-1272	small-molecule	_	_	
7-30	1273-1280	ligands	_	_	
7-31	1281-1285	that	_	_	
7-32	1286-1296	presumably	_	_	
7-33	1297-1301	bind	_	_	
7-34	1302-1304	at	_	_	
7-35	1305-1306	a	_	_	
7-36	1307-1313	common	_	_	
7-37	1314-1318	site	_	_	
7-38	1319-1321	on	_	_	
7-39	1322-1325	the	_	_	
7-40	1326-1332	target	_	_	
7-41	1333-1344	biomolecule	_	_	
7-42	1344-1345	.	_	_	
7-43	1346-1347	[	_	_	
7-44	1347-1351	0185	_	_	
7-45	1351-1352	]	_	_	
7-46	1353-1354	A	_	_	
7-47	1355-1362	variety	_	_	
7-48	1363-1365	of	_	_	
7-49	1366-1375	screening	_	_	
7-50	1376-1386	approaches	_	_	
7-51	1387-1390	can	_	_	
7-52	1391-1393	be	_	_	
7-53	1394-1398	used	_	_	
7-54	1399-1401	to	_	_	
7-55	1402-1408	obtain	_	_	
7-56	1409-1416	ligands	_	_	
7-57	1417-1421	that	_	_	
7-58	1422-1429	possess	_	_	
7-59	1430-1434	high	_	_	
7-60	1435-1443	affinity	_	_	
7-61	1444-1447	for	_	_	
7-62	1448-1451	one	_	_	
7-63	1452-1458	target	_	_	
7-64	1459-1462	but	_	_	
7-65	1463-1476	significantly	_	_	
7-66	1477-1483	weaker	_	_	
7-67	1484-1492	affinity	_	_	
7-68	1493-1496	for	_	_	
7-69	1497-1504	another	_	_	
7-70	1505-1512	closely	_	_	
7-71	1513-1520	related	_	_	
7-72	1521-1527	target	_	_	
7-73	1527-1528	.	_	_	

#Text=One screening strategy is to identify ligands for both biomolecules in parallel experiments and to subsequently eliminate common ligands by a cross-referencing comparison.
8-1	1529-1532	One	*[1]	9-2[2_1]|10-1[3_1]	
8-2	1533-1542	screening	*[1]	_	
8-3	1543-1551	strategy	*[1]	_	
8-4	1552-1554	is	*[1]	_	
8-5	1555-1557	to	*[1]	_	
8-6	1558-1566	identify	*[1]	_	
8-7	1567-1574	ligands	*[1]	_	
8-8	1575-1578	for	*[1]	_	
8-9	1579-1583	both	*[1]	_	
8-10	1584-1596	biomolecules	*[1]	_	
8-11	1597-1599	in	*[1]	_	
8-12	1600-1608	parallel	*[1]	_	
8-13	1609-1620	experiments	*[1]	_	
8-14	1621-1624	and	*[1]	_	
8-15	1625-1627	to	*[1]	_	
8-16	1628-1640	subsequently	*[1]	_	
8-17	1641-1650	eliminate	*[1]	_	
8-18	1651-1657	common	*[1]	_	
8-19	1658-1665	ligands	*[1]	_	
8-20	1666-1668	by	*[1]	_	
8-21	1669-1670	a	*[1]	_	
8-22	1671-1688	cross-referencing	*[1]	_	
8-23	1689-1699	comparison	*[1]	_	
8-24	1699-1700	.	*[1]	_	

#Text=In this method, ligands for each biomolecule can be separately identified as disclosed above.
9-1	1701-1703	In	_	_	
9-2	1704-1708	this	*[2]	_	
9-3	1709-1715	method	*[2]	_	
9-4	1715-1716	,	_	_	
9-5	1717-1724	ligands	_	_	
9-6	1725-1728	for	_	_	
9-7	1729-1733	each	_	_	
9-8	1734-1745	biomolecule	_	_	
9-9	1746-1749	can	_	_	
9-10	1750-1752	be	_	_	
9-11	1753-1763	separately	_	_	
9-12	1764-1774	identified	_	_	
9-13	1775-1777	as	_	_	
9-14	1778-1787	disclosed	_	_	
9-15	1788-1793	above	_	_	
9-16	1793-1794	.	_	_	

#Text=This method is compatible with both immobilized target biomolecules and target biomolecules free in solution.
#Text=[0186] For immobilized target biomolecules, another strategy is to add a preselection step that eliminates all ligands that bind to the non-target biomolecule from the library.
10-1	1795-1799	This	*[3]	_	
10-2	1800-1806	method	*[3]	_	
10-3	1807-1809	is	_	_	
10-4	1810-1820	compatible	_	_	
10-5	1821-1825	with	_	_	
10-6	1826-1830	both	_	_	
10-7	1831-1842	immobilized	_	_	
10-8	1843-1849	target	_	_	
10-9	1850-1862	biomolecules	_	_	
10-10	1863-1866	and	_	_	
10-11	1867-1873	target	_	_	
10-12	1874-1886	biomolecules	_	_	
10-13	1887-1891	free	_	_	
10-14	1892-1894	in	_	_	
10-15	1895-1903	solution	_	_	
10-16	1903-1904	.	_	_	
10-17	1905-1906	[	_	_	
10-18	1906-1910	0186	_	_	
10-19	1910-1911	]	_	_	
10-20	1912-1915	For	_	_	
10-21	1916-1927	immobilized	_	_	
10-22	1928-1934	target	_	_	
10-23	1935-1947	biomolecules	_	_	
10-24	1947-1948	,	_	_	
10-25	1949-1956	another	_	_	
10-26	1957-1965	strategy	_	_	
10-27	1966-1968	is	_	_	
10-28	1969-1971	to	_	_	
10-29	1972-1975	add	_	_	
10-30	1976-1977	a	_	_	
10-31	1978-1990	preselection	_	_	
10-32	1991-1995	step	_	_	
10-33	1996-2000	that	_	_	
10-34	2001-2011	eliminates	_	_	
10-35	2012-2015	all	_	_	
10-36	2016-2023	ligands	_	_	
10-37	2024-2028	that	_	_	
10-38	2029-2033	bind	_	_	
10-39	2034-2036	to	_	_	
10-40	2037-2040	the	_	_	
10-41	2041-2051	non-target	_	_	
10-42	2052-2063	biomolecule	_	_	
10-43	2064-2068	from	_	_	
10-44	2069-2072	the	_	_	
10-45	2073-2080	library	_	_	
10-46	2080-2081	.	_	_	

#Text=For example, a first biomolecule can be contacted with an encoded library as described above.
11-1	2082-2085	For	_	_	
11-2	2086-2093	example	_	_	
11-3	2093-2094	,	_	_	
11-4	2095-2096	a	_	_	
11-5	2097-2102	first	_	_	
11-6	2103-2114	biomolecule	_	_	
11-7	2115-2118	can	_	_	
11-8	2119-2121	be	_	_	
11-9	2122-2131	contacted	_	_	
11-10	2132-2136	with	_	_	
11-11	2137-2139	an	_	_	
11-12	2140-2147	encoded	_	_	
11-13	2148-2155	library	_	_	
11-14	2156-2158	as	_	_	
11-15	2159-2168	described	_	_	
11-16	2169-2174	above	_	_	
11-17	2174-2175	.	_	_	

#Text=Compounds which do not bind to the first biomolecule are then separated from any first biomolecule-ligand complexes which form.
12-1	2176-2185	Compounds	_	_	
12-2	2186-2191	which	_	_	
12-3	2192-2194	do	_	_	
12-4	2195-2198	not	_	_	
12-5	2199-2203	bind	_	_	
12-6	2204-2206	to	_	_	
12-7	2207-2210	the	_	_	
12-8	2211-2216	first	_	_	
12-9	2217-2228	biomolecule	_	_	
12-10	2229-2232	are	_	_	
12-11	2233-2237	then	_	_	
12-12	2238-2247	separated	_	_	
12-13	2248-2252	from	_	_	
12-14	2253-2256	any	_	_	
12-15	2257-2262	first	_	_	
12-16	2263-2281	biomolecule-ligand	_	_	
12-17	2282-2291	complexes	_	_	
12-18	2292-2297	which	_	_	
12-19	2298-2302	form	_	_	
12-20	2302-2303	.	_	_	

#Text=The second biomolecule is then contacted with the compounds which did not bind to the first biomolecule.
13-1	2304-2307	The	_	_	
13-2	2308-2314	second	_	_	
13-3	2315-2326	biomolecule	_	_	
13-4	2327-2329	is	_	_	
13-5	2330-2334	then	_	_	
13-6	2335-2344	contacted	_	_	
13-7	2345-2349	with	_	_	
13-8	2350-2353	the	_	_	
13-9	2354-2363	compounds	_	_	
13-10	2364-2369	which	_	_	
13-11	2370-2373	did	_	_	
13-12	2374-2377	not	_	_	
13-13	2378-2382	bind	_	_	
13-14	2383-2385	to	_	_	
13-15	2386-2389	the	_	_	
13-16	2390-2395	first	_	_	
13-17	2396-2407	biomolecule	_	_	
13-18	2407-2408	.	_	_	

#Text=Compounds which bind to the second biomolecule can be identified as described above and have significantly greater affinity for the second biomolecule than to the first biomolecule.
#Text=[0187] A ligand for a biomolecule of unknown function which is identified by the method disclosed above can also be used to determine the biological function of the biomolecule.
14-1	2409-2418	Compounds	_	_	
14-2	2419-2424	which	_	_	
14-3	2425-2429	bind	_	_	
14-4	2430-2432	to	_	_	
14-5	2433-2436	the	_	_	
14-6	2437-2443	second	_	_	
14-7	2444-2455	biomolecule	_	_	
14-8	2456-2459	can	_	_	
14-9	2460-2462	be	_	_	
14-10	2463-2473	identified	_	_	
14-11	2474-2476	as	_	_	
14-12	2477-2486	described	_	_	
14-13	2487-2492	above	_	_	
14-14	2493-2496	and	_	_	
14-15	2497-2501	have	_	_	
14-16	2502-2515	significantly	_	_	
14-17	2516-2523	greater	_	_	
14-18	2524-2532	affinity	_	_	
14-19	2533-2536	for	_	_	
14-20	2537-2540	the	_	_	
14-21	2541-2547	second	_	_	
14-22	2548-2559	biomolecule	_	_	
14-23	2560-2564	than	_	_	
14-24	2565-2567	to	_	_	
14-25	2568-2571	the	_	_	
14-26	2572-2577	first	_	_	
14-27	2578-2589	biomolecule	_	_	
14-28	2589-2590	.	_	_	
14-29	2591-2592	[	_	_	
14-30	2592-2596	0187	_	_	
14-31	2596-2597	]	_	_	
14-32	2598-2599	A	_	_	
14-33	2600-2606	ligand	_	_	
14-34	2607-2610	for	_	_	
14-35	2611-2612	a	_	_	
14-36	2613-2624	biomolecule	_	_	
14-37	2625-2627	of	_	_	
14-38	2628-2635	unknown	_	_	
14-39	2636-2644	function	_	_	
14-40	2645-2650	which	_	_	
14-41	2651-2653	is	_	_	
14-42	2654-2664	identified	_	_	
14-43	2665-2667	by	_	_	
14-44	2668-2671	the	_	_	
14-45	2672-2678	method	_	_	
14-46	2679-2688	disclosed	_	_	
14-47	2689-2694	above	_	_	
14-48	2695-2698	can	_	_	
14-49	2699-2703	also	_	_	
14-50	2704-2706	be	_	_	
14-51	2707-2711	used	_	_	
14-52	2712-2714	to	_	_	
14-53	2715-2724	determine	_	_	
14-54	2725-2728	the	_	_	
14-55	2729-2739	biological	_	_	
14-56	2740-2748	function	_	_	
14-57	2749-2751	of	_	_	
14-58	2752-2755	the	_	_	
14-59	2756-2767	biomolecule	_	_	
14-60	2767-2768	.	_	_	

#Text=This is advantageous because although new gene sequences continue to be identified, the functions of the proteins encoded by these sequences and the validity of these proteins as targets for new drug discovery and development are difficult to determine and represent perhaps the most significant obstacle to applying genomic information to the treatment of disease.
15-1	2769-2773	This	_	_	
15-2	2774-2776	is	_	_	
15-3	2777-2789	advantageous	_	_	
15-4	2790-2797	because	_	_	
15-5	2798-2806	although	_	_	
15-6	2807-2810	new	_	_	
15-7	2811-2815	gene	_	_	
15-8	2816-2825	sequences	_	_	
15-9	2826-2834	continue	_	_	
15-10	2835-2837	to	_	_	
15-11	2838-2840	be	_	_	
15-12	2841-2851	identified	_	_	
15-13	2851-2852	,	_	_	
15-14	2853-2856	the	_	_	
15-15	2857-2866	functions	_	_	
15-16	2867-2869	of	_	_	
15-17	2870-2873	the	_	_	
15-18	2874-2882	proteins	_	_	
15-19	2883-2890	encoded	_	_	
15-20	2891-2893	by	_	_	
15-21	2894-2899	these	_	_	
15-22	2900-2909	sequences	_	_	
15-23	2910-2913	and	_	_	
15-24	2914-2917	the	_	_	
15-25	2918-2926	validity	_	_	
15-26	2927-2929	of	_	_	
15-27	2930-2935	these	_	_	
15-28	2936-2944	proteins	_	_	
15-29	2945-2947	as	_	_	
15-30	2948-2955	targets	_	_	
15-31	2956-2959	for	_	_	
15-32	2960-2963	new	_	_	
15-33	2964-2968	drug	_	_	
15-34	2969-2978	discovery	_	_	
15-35	2979-2982	and	_	_	
15-36	2983-2994	development	_	_	
15-37	2995-2998	are	_	_	
15-38	2999-3008	difficult	_	_	
15-39	3009-3011	to	_	_	
15-40	3012-3021	determine	_	_	
15-41	3022-3025	and	_	_	
15-42	3026-3035	represent	_	_	
15-43	3036-3043	perhaps	_	_	
15-44	3044-3047	the	_	_	
15-45	3048-3052	most	_	_	
15-46	3053-3064	significant	_	_	
15-47	3065-3073	obstacle	_	_	
15-48	3074-3076	to	_	_	
15-49	3077-3085	applying	_	_	
15-50	3086-3093	genomic	_	_	
15-51	3094-3105	information	_	_	
15-52	3106-3108	to	_	_	
15-53	3109-3112	the	_	_	
15-54	3113-3122	treatment	_	_	
15-55	3123-3125	of	_	_	
15-56	3126-3133	disease	_	_	
15-57	3133-3134	.	_	_	

#Text=Target-specific ligands obtained through the process described in this invention can be effectively employed in whole cell biological assays or in appropriate animal models to understand both the function of the target protein and the validity of the target protein for therapeutic intervention.
16-1	3135-3150	Target-specific	_	_	
16-2	3151-3158	ligands	_	_	
16-3	3159-3167	obtained	_	_	
16-4	3168-3175	through	_	_	
16-5	3176-3179	the	_	_	
16-6	3180-3187	process	_	_	
16-7	3188-3197	described	_	_	
16-8	3198-3200	in	_	_	
16-9	3201-3205	this	_	_	
16-10	3206-3215	invention	_	_	
16-11	3216-3219	can	_	_	
16-12	3220-3222	be	_	_	
16-13	3223-3234	effectively	_	_	
16-14	3235-3243	employed	_	_	
16-15	3244-3246	in	_	_	
16-16	3247-3252	whole	_	_	
16-17	3253-3257	cell	_	_	
16-18	3258-3268	biological	_	_	
16-19	3269-3275	assays	_	_	
16-20	3276-3278	or	_	_	
16-21	3279-3281	in	_	_	
16-22	3282-3293	appropriate	_	_	
16-23	3294-3300	animal	_	_	
16-24	3301-3307	models	_	_	
16-25	3308-3310	to	_	_	
16-26	3311-3321	understand	_	_	
16-27	3322-3326	both	_	_	
16-28	3327-3330	the	_	_	
16-29	3331-3339	function	_	_	
16-30	3340-3342	of	_	_	
16-31	3343-3346	the	_	_	
16-32	3347-3353	target	_	_	
16-33	3354-3361	protein	_	_	
16-34	3362-3365	and	_	_	
16-35	3366-3369	the	_	_	
16-36	3370-3378	validity	_	_	
16-37	3379-3381	of	_	_	
16-38	3382-3385	the	_	_	
16-39	3386-3392	target	_	_	
16-40	3393-3400	protein	_	_	
16-41	3401-3404	for	_	_	
16-42	3405-3416	therapeutic	_	_	
16-43	3417-3429	intervention	_	_	
16-44	3429-3430	.	_	_	

#Text=This approach can also confirm that the target is specifically amenable to small molecule drug discovery.
17-1	3431-3435	This	_	_	
17-2	3436-3444	approach	_	_	
17-3	3445-3448	can	_	_	
17-4	3449-3453	also	_	_	
17-5	3454-3461	confirm	_	_	
17-6	3462-3466	that	_	_	
17-7	3467-3470	the	_	_	
17-8	3471-3477	target	_	_	
17-9	3478-3480	is	_	_	
17-10	3481-3493	specifically	_	_	
17-11	3494-3502	amenable	_	_	
17-12	3503-3505	to	_	_	
17-13	3506-3511	small	_	_	
17-14	3512-3520	molecule	_	_	
17-15	3521-3525	drug	_	_	
17-16	3526-3535	discovery	_	_	
17-17	3535-3536	.	_	_	
